Dr. Force is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Bryan Searle Drive Seeley Mudd Building Room 449b
Durham, NC 27710Phone+1 919-613-6891
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2014 - 2017
Indiana University School of MedicineResidency, Internal Medicine, 2011 - 2014
University of New England College of Osteopathic MedicineClass of 2011
Boston University School of MedicineM.A., Medical Science, Cum Laude, 2004 - 2005
University of Rhode IslandB.A., Philosophy, 1997 - 2001- University of Rhode IslandB.S., Biology, 1997 - 2001
Certifications & Licensure
NC State License 2014 - 2025
IN State License 2013 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Outstanding Internal Medicine Resident In Geriatric Medicine 2014
- Who’s Who Among Students in American Universities & Colleges 2011
- Robert Bessette D.O. Scholarship Award 2008
- Join now to see all
Clinical Trials
- A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer Start of enrollment: 2022 Apr 07
- A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Start of enrollment: 2016 May 31
Roles: Contact
Publications & Presentations
PubMed
- 111 citationsThe Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patie...Oluwadamilola M. Fayanju, Yi Ren, Samantha M. Thomas, Rachel A. Greenup, Jennifer K. Plichta
Annals of Surgery. 2018-10-01 - 33 citationsRIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrenceChao-Chieh Lin, Nathaniel W. Mabe, Yi-Tzu Lin, Wen-Hsuan Yang, Xiaohu Tang
Cell Death and Differentiation. 2020-01-27 - 2 citationsDiscovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors.Sudarshan R Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Clare Keddy
EMBO Molecular Medicine. 2023-10-11
Journal Articles
- Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology DatabaseAllison Hall, Jeremy Force, Oluwadamilola M Fayanju, E Shelley Hwang, Cecilia T Ong, Laura H Rosenberger, Jennifer K Plichta, Rachel A Greenup, Annals of Surgical Oncology
Press Mentions
Duke, UNC Researchers Receiving $1.5 Million for Breast Cancer Research Will Study Vaccines, Death Rates in Black WomenOctober 13th, 2021- Duke, UNC Teams Geting $1.5 Million for Breast Cancer Research Will Study Vaccines, Death Rates in Black WomenOctober 13th, 2021
- Duke, UNC Teams Getting $1.5 Million for Breast Cancer Research Will Study Vaccines, Death Rates in Black WomenOctober 13th, 2021
Research History
- National Institutes of Health - Clinical Research Training Program, Research FellowMentor: Giuseppe Giaccone, M.D., Ph.D.2009 - 2010
- Summer Research Student - Harvard Medical School/Dana Farber Cancer InstituteMentor: Kwok Wong, M.D., Ph.D.2007 - 2008
- Research Technician - Harvard Medical School/Children's Hospital BostonMentor: Judah Folkman, M.D.; John Heymach, M.D., Ph.D.2002 - 2005
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
